Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On February 19, 2019, the Patented Medicine Prices Review Board
(PMPRB) announced the publication of the 2017 edition
of Meds Entry Watch. According to the notice, this
publication provides information on new medicines entering Canadian
and international markets. The 2017 edition examines the
availability, sales, uptake, pricing, and treatment costs of new
medicines approved by the US Food and Drug Administration, the
European Medicines Agency, and/or Health Canada in 2016 and 2017,
as well as trends, going back to 2009. This edition also includes
an analysis of biosimilars approved between 2006 and 2017.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
